Alexion Pharmaceuticals (ALXN) : Iguana Healthcare Management scooped up 25,000 additional shares in Alexion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 75,000 shares of Alexion Pharmaceuticals which is valued at $8,916,750.Alexion Pharmaceuticals makes up approximately 4.10% of Iguana Healthcare Management’s portfolio.
Other Hedge Funds, Including , Raymond James Associates reduced its stake in ALXN by selling 1,047 shares or 0.51% in the most recent quarter. The Hedge Fund company now holds 205,874 shares of ALXN which is valued at $24,476,360. Alexion Pharmaceuticals makes up approx 0.07% of Raymond James Associates’s portfolio.Stephens Inc Ar boosted its stake in ALXN in the latest quarter, The investment management firm added 337 additional shares and now holds a total of 2,769 shares of Alexion Pharmaceuticals which is valued at $351,331. Alexion Pharmaceuticals makes up approx 0.02% of Stephens Inc Ar’s portfolio.Pitcairn Co boosted its stake in ALXN in the latest quarter, The investment management firm added 6,242 additional shares and now holds a total of 26,896 shares of Alexion Pharmaceuticals which is valued at $3,420,095. Alexion Pharmaceuticals makes up approx 0.43% of Pitcairn Co’s portfolio.Winslow Capital Management reduced its stake in ALXN by selling 26 shares or 7.54% in the most recent quarter. The Hedge Fund company now holds 319 shares of ALXN which is valued at $40,749.
Alexion Pharmaceuticals closed down -3.12 points or -2.54% at $119.85 with 15,23,614 shares getting traded on Monday. Post opening the session at $122.49, the shares hit an intraday low of $119.7 and an intraday high of $124.04 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alexion Pharmaceuticals reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $1.17. The company had revenue of $799.10 million for the quarter, compared to analysts expectations of $786.61 million. The company’s revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Deutsche Bank Initiated Alexion Pharmaceuticals on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $164.Alexion Pharmaceuticals was Upgraded by Goldman to ” Buy” on Oct 28, 2016. Company shares were Reiterated by Wedbush on Oct 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 135 from a previous price target of $132 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.